By Professor Nada Hamad

Journal articles

Hamad N; Gottlieb D; Ritchie D; Kennedy G; Watson AM; Greenwood M; Doocey R; Perera T; Spencer A; Wong E; O'Brien T; Shaw P; Conyers R; Cole T; Milliken S; Bardy P; Larsen S; Lai H; Butler A; Fraser C; Bajel A; Butler J; Kerridge I; Purtill D, 2020, 'Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement', Internal Medicine Journal, 50, pp. 774 - 775, http://dx.doi.org/10.1111/imj.14867

Casasnovas RO; Daniele P; Tremblay G; Maerevoet M; Zijlstra J; Follows G; Vermaat JSP; Kalakonda N; Goy AH; Choquet S; Van Den Neste E; Hill BT; Thieblemont C; Cavallo F; de la Cruz F; Kuruvilla J; Hamad N; Bouabdallah R; Jäger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vasilakopoulos T; Samal P; Nagy A; Ku M; Canales Albendea MÁ, 2020, 'PCN325 Health Utility in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) Patients - Results of a Phase II Trial with ORAL Selinexor', Value in Health, 23, pp. S479 - S480, http://dx.doi.org/10.1016/j.jval.2020.08.462

Gerstl B; Sullivan E; Koch J; Wand H; Ives A; Mitchell R; Hamad N; Anazodo A, 2019, 'Reproductive outcomes following a stem cell transplant for a haematological malignancy in female cancer survivors: a systematic review and meta-analysis', Supportive Care in Cancer, 27, pp. 4451 - 4460, http://dx.doi.org/10.1007/s00520-019-05020-8

Lwin Y; He SZ-X; Spencer A; Purtill D; Mcewan A; Browett P; Butler A; Carter J; Bardy PG; Kennedy GA; Szer J; Ritchie D; Greenwood M; Larsen SR; Milliken S; Lai HC; Gottlieb D; Kwan J; Aarons D; Tran S; Hamad N, 2019, 'An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era', Blood, 134, pp. 5719 - 5719, http://dx.doi.org/10.1182/blood-2019-126547

Park JH; Woo YM; Youm EM; Hamad N; Won HH; Naka K; Park EJ; Park JH; Kim HJ; Kim SH; Kim HJ; Ahn JS; Sohn SK; Moon JH; Jung CW; Park S; Lipton JH; Kimura S; Kim JW; Kim DH, 2019, 'HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia', Leukemia, 33, pp. 1439 - 1450, http://dx.doi.org/10.1038/s41375-018-0321-8

McCarthy R-L; McNamee N; Copelin B; Mills G; Wong S; Qiu MR; Earls P; Milliken S; Hamad N; Fay K; Lukeis R; Parker A; Moore J, 2019, 'A case series of langerhans cell histiocytosis with braf testing', Pathology, 51, pp. S92 - S92, http://dx.doi.org/10.1016/j.pathol.2018.12.243

Lewis KL; Dowling M; Bavishi K; Øvlisen AK; Hamad N; Choi P; Grigg A; P'Ng S; Filshie R; Ritchie DS; Bilmon I; Prince HM; Wolf M; Hertzberg M; Chuah H; El‐Galaly TC; Tam CS; Seymour JF; Cheah CY, 2019, 'CLINICAL OUTCOMES FROM VENETOCLAX BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMAS', Hematological Oncology, 37, pp. 535 - 537, http://dx.doi.org/10.1002/hon.221_2631

Poch Martell M; Hamad N; Shin E; Moon JH; Sohn SK; Uhm J; Michelis FV; Viswabandya A; Lipton JH; Messner HA; Kim DDH, 2017, 'Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data', European Journal of Haematology, 99, pp. 160 - 168, http://dx.doi.org/10.1111/ejh.12899

Moon JH; Hamad N; Sohn SK; Uhm J; Alam N; Gupta V; Lipton JH; Messner HA; Seftel M; Kuruvilla J; Kim DH, 2017, 'Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD', Annals of Hematology, 96, pp. 805 - 815, http://dx.doi.org/10.1007/s00277-017-2939-4

Zheng Q; Cao J; Hamad N; Kim HJ; Moon JH; Sohn SK; Jung CW; Lipton JH; Kim DDH, 2016, 'Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia', Journal of Translational Medicine, 14, pp. 82, http://dx.doi.org/10.1186/s12967-016-0837-5

Hamad N; Armytage T; McIlroy K; Singh N; Ward C, 2015, 'Primary cutaneous mantle-cell lymphoma: A case report and literature review', Journal of Clinical Oncology, 33, pp. e104 - e108, http://dx.doi.org/10.1200/JCO.2012.47.2829

Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DDH, 2015, 'Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation', American Journal of Hematology, 90, pp. 392 - 399, http://dx.doi.org/10.1002/ajh.23955

Hamad N; Kliman D; Best OG; Caramins M; Hertzberg M; Lindeman R; Porter R; Mulligan SP, 2015, 'Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: Five cases, a literature review and discussion of management', British Journal of Haematology, 168, pp. 350 - 360, http://dx.doi.org/10.1111/bjh.13134

Al-Daraiseh AA; Al Omari D; Al Hamid H; Hamad N; Althemali R, 2015, 'Effectiveness of Iphone's Touch ID: KSA Case Study', INTERNATIONAL JOURNAL OF ADVANCED COMPUTER SCIENCE AND APPLICATIONS, 6, pp. 154 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357578700022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Uhm J; Hamad N; Shin EM; Michelis FV; Shanavas M; Gupta V; Kuruvilla J; Lipton JH; Messner HA; Seftel M; Kim DDH, 2014, 'Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation', Biology of Blood and Marrow Transplantation, 20, pp. 1751 - 1757, http://dx.doi.org/10.1016/j.bbmt.2014.07.001

Hamad N; Del Bel R; Messner HA; Kim D; Kuruvilla J; Lipton JH; Uhm J; Seftel M; Alam N; Xu W; Gupta V, 2014, 'Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning', Biology of Blood and Marrow Transplantation, 20, pp. 1722 - 1728, http://dx.doi.org/10.1016/j.bbmt.2014.06.033

Kim D; Hamad N; Lee HG; Kamel-Reid S; Lipton JH, 2014, 'BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase', American Journal of Hematology, 89, pp. 626 - 632, http://dx.doi.org/10.1002/ajh.23707

Kim D; Won HH; Su S; Cheng L; Xu W; Hamad N; Uhm J; Gupta V; Kuruvilla J; Messner HA; Lipton JH, 2014, 'Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models', Bone Marrow Transplantation, 49, pp. 649 - 656, http://dx.doi.org/10.1038/bmt.2014.20

Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D, 2014, 'Validation of national institutes of health global scoring system for chronic Graft-Versus-Host Disease (GVHD) according to overall and GVHD-specific survival', Biology of Blood and Marrow Transplantation, 20, pp. 556 - 563, http://dx.doi.org/10.1016/j.bbmt.2014.01.010

Hamad N; Kliman D; Best OG; Caramins M; Hertzberg M; Lindeman R; Porter R; Mulligan SP, 2014, 'Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: Five cases, a literature review and discussion of management', British Journal of Haematology, http://dx.doi.org/10.1111/bjh.13134

Shanavas M; Hamad N; Michelis FV; Uhm J; Gupta V; Kuruvilla J; Messner HA; Lipton JH; Hwan Kim DD, 2013, 'Risk Factors For Chronic Eye and Mouth GVHD In Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable', Blood, 122, pp. 4601 - 4601, http://dx.doi.org/10.1182/blood.v122.21.4601.4601

Back to profile page